Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
1.25 1.07 1.02 0.82
P/FCF ratio
9.77 9.07 7.52 7.04
P/Operating CF
48.38 40.20 17.87 15.48
P/B ratio
1.30 1.06 0.99 0.76
EV/Sales
2.10 1.93 1.93 1.90
EV/EBITDA
11.39 9.55 9.01 8.75
EV/FCF
16.36 16.35 14.27 16.38
Current Ratio
1.58 1.60 1.38 1.35
Net Debt/EBITDA
18.37 21.03 22.80 17.63
Debt/Equity
0.94 0.98 0.98 1.07
Earnings Yield
(2.27%) (1.95%) (23.81%) (31.25%)
Free Cash Flow Yield
10.23% 11.03% 13.30% 14.20%
Free Cash Flow per Share
0.29 0.23 0.55 0.55
Book value per Share
12.26 12.69 12.57 13.07
Free Cash Flow
336.20 268.00 640.40 646.00
EV/EBIT
0.00 201.94 0.00 0.00
Other line items

Show all line items

Columns are period end dates